Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jun;133(3):537-41.
doi: 10.1016/j.ygyno.2014.02.036. Epub 2014 Mar 1.

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study

Susana M Campos  1 , William E Brady  2 , Katherine M Moxley  3 , Roisin E O'Cearbhaill  4 , Paula S Lee  5 , Paul A DiSilvestro  6 , Jacob Rotmensch  7 , Peter G Rose  8 , Premal H Thaker  9 , David M O'Malley  10 , Parviz Hanjani  11 , Rosemary E Zuna  3 , Martee L Hensley  4
Affiliations
Clinical Trial

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study

Susana M Campos et al. Gynecol Oncol. 2014 Jun.

Erratum in

  • Gynecol Oncol. 2014 Dec;135(3):624

Abstract

Objective: Carcinosarcomas of the female genital tract, also called malignant mixed müllerian tumors, are aggressive biphasic tumors. Second-line treatment options in the recurrent/persistent setting have yielded marginal responses. Given the potential role of angiogenesis in the gynecological carcinomas, pazopanib, a VEGFR inhibitor, was investigated in the management of patients with recurrent carcinosarcoma of the uterus.

Methods: Eligible patients had histologically confirmed carcinosarcoma of the uterus, a maximum of two prior lines of therapy, adequate renal, hepatic and hematologic function and a performance status of 0-2. Pazopanib was administered orally at 800mg. Two dose reductions were allowed. The primary objective was to ascertain the activity of pazopanib as measured by the proportion of patients who survive progression-free for at least six months and the proportion of patients that have objective tumor responses. Secondary objectives included the frequency and severity of adverse events as assessed by CTCAE v4.0.

Results: Of the 22 enrolled patients, 19 were eligible and evaluable for toxicity and survival. No patients had a partial or complete response (90% confidence interval [CI]: 0%, 14.6%). Three patients (15.8%) had PFS ≥6months (90% CI: 4.4%, 35.9%). The median PFS was 2.0months (first and third quartiles were 1.6 and 4.0months, respectively). The median overall survival was 8.7months (first and third quartiles were 2.6 and 14.0months, respectively).

Conclusion: Pazopanib demonstrated minimal activity as a second or third line treatment for advanced uterine carcinosarcoma. Potential clinical trial participation should be discussed with the patients.

Keywords: Angiogenesis; Carcinosarcoma; Uterus; VEGFR inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Overall and Progression-Free Survival
Kaplan – Meier estimate of progression free survival (PFS) and overall survival (OS) for all eligible and evaluable patients on the study
See this image and copyright information in PMC

References

    1. Auerbach HE, LiVolsi VA, Merino MJ. Malignant mixed Mullerian tumors of the uterus. An immunohistochemical study. Int J Gynecol Path. 1988;7:123–30. - PubMed
    1. De Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor of the female genital tract: immunohistochemical and ultrastructural analysis 28 cases. Hum Path. 1993;24:132–42. - PubMed
    1. Chung MT, Mukai K, Teshima S, Kishi K, Shimosato Y. Expression of various antigens by different components of uterine mixed Mullerian tumors. An immunohistochemical study. Acta Pathol Jpn. 1988;38:35–45. - PubMed
    1. Costa MJ, Khan R, Judd R. Carcinoma (malignant mixed mullerian {mesodermal tumor] of the uterus and ovary. Correlation of clinical, pathologic and immunohistochemical features in 29 cases. Arch Pathol Lab Med. 1991;115:583–90. - PubMed
    1. Emoto M, Iwasaki H, Kikuchi M, Ishiguro M, Kubota T, Izumi H, et al. Two cell lines established from mixed mullerian tumors of the uterus. Morphological, immunocytochemical and cytogenetic analyses. Cancer. 1992;69:1759–68. - PubMed

Publication types

MeSH terms